TB 500: What It Is and What Research Shows

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

What is TB 500, exactly?

TB-500 is a lab-made peptide. Chemically, it is a short chain of seven amino acids with an acetyl group on the front end — written as Ac-LKKTETQ. That sequence is not invented from scratch: it is copied directly from one active region of a larger natural protein called thymosin beta-4 (often written Tβ4). Specifically, TB-500 corresponds to residues 17 through 23 of thymosin beta-4 — the part of the protein that binds actin, one of the core structural proteins inside your cells.

So the honest one-line description is this: TB-500 is a synthetic fragment that mimics a small, functionally important piece of a much bigger natural protein. It is a peptide, not a steroid and not a hormone in the testosterone sense. That biological plausibility is part of why it attracts interest — but interest and proof are very different things, and the gap between them is the theme of this guide. You will see TB-500 sold online as a "research chemical," usually a freeze-dried powder in a vial — not a supplement and not an approved medicine. In Australia and New Zealand it is prescription-only, and it has turned up as a designer doping agent in racehorses. None of that makes it a safe, tested product.

Is TB 500 the same as thymosin beta-4?

No — and this is the single most important distinction on this page, because a lot of the marketing depends on blurring it. Thymosin beta-4 is the full, natural protein: 43 amino acids, present in nearly every cell. TB-500 is a 7-amino-acid fragment of it, made synthetically. Related, yes; identical, no.

Why does the distinction matter so much? Because the genuine human clinical data belongs to the full protein, formulated as a drug (RGN-259) and delivered in narrow medical settings — an eye drop or a topical wound treatment. It does not belong to the injected TB-500 fragment biohackers use for muscle and tendon recovery. When a vendor points to "thymosin beta-4 clinical trials" as evidence for injecting TB-500 into a sore shoulder, they are quietly swapping one molecule and route of delivery for a completely different one.

Feature	Thymosin beta-4 (parent protein)	TB-500 (fragment)
Size	Full 43-amino-acid protein, naturally occurring	7-amino-acid synthetic fragment (Ac-LKKTETQ)
Human trials?	Yes — registered Phase 2/3 for eye and skin healing (as RGN-259)	No completed published human RCT for injury or athletic use
How studied in humans	Eye drop and topical/dermal drug in medical settings	Self-injected on the gray market — not in controlled trials
FDA status	Investigational; not an approved product	Not approved; not on the 503A Bulks List

We cover the biology of the full protein and its actual human clinical program — including a Phase 3 trial that failed its primary endpoint — in our deep dive on thymosin beta-4, the parent protein behind TB-500. If you only remember one thing from this section, make it this: the real human evidence is for the parent protein as an eye or skin drug, not for injecting the fragment.

What does TB 500 do to the body, and what has research investigated?

Here precision matters most. The mechanism researchers describe for thymosin beta-4 — and the fragment TB-500 mimics — starts with actin sequestration: thymosin beta-4 binds and holds a pool of free actin monomers, and releasing that pool lets cells rebuild their internal scaffolding and migrate, a step involved in wound closure. A 2021 review catalogs this alongside VEGF-driven angiogenesis and anti-inflammatory signaling, while the foundational 2004 Nature paper showed thymosin beta-4 activating the ILK/Akt survival pathway and promoting heart and endothelial cell migration and repair — in animal models.

Read those verbs carefully. "Promotes cell migration," "activates a survival pathway," "drives angiogenesis" — these describe what researchers observed in cells and animals, not outcomes in people injecting TB-500. Below is a high-level map; nothing in it is a proven human benefit of the fragment.

Area studied	What research investigated	Evidence type
Cell migration & tissue repair	Actin sequestration mobilizing the G-actin pool for cytoskeletal remodeling	Cell / animal / preclinical
Angiogenesis	VEGF upregulation and endothelial-cell migration	Mechanism / animal
Cardiac repair	Post-MI cell survival and function via ILK/Akt (parent protein)	Animal / preclinical
Dermal / wound healing	Pressure ulcers, venous stasis ulcers, epidermolysis bullosa (parent protein)	Human Phase 2 signals (parent protein)
Corneal / ocular healing	Dry eye and neurotrophic keratopathy (as the RGN-259 eye drop)	Human Phase 2/3 (parent protein) — mixed results
Muscle / soft-tissue "recovery"	The biohacker injury-recovery claim for injected TB-500	Preclinical only — no completed human RCT

The dermal signals come from human Phase 2 work in pressure ulcers, venous stasis ulcers, and epidermolysis bullosa, using the full protein topically. The strongest human data is ophthalmic — the RGN-259 eye drop — including a placebo-controlled Phase 3 readout in neurotrophic keratopathy. Even there the picture is mixed: a separate confirmatory EU Phase 3 (SEER-3) missed its primary endpoint. And the most direct source on the injury question — a 2026 scoping review of thymosin beta-4 and TB-500 in tissue healing and musculoskeletal repair — concludes the evidence is largely preclinical, with limited human data. For the fragment sold as an injury peptide, human evidence is essentially absent.

For the full benefit-by-benefit breakdown — tissue repair, angiogenesis, cardiac, dermal, corneal, and the muscle-recovery claim, each with the human-evidence flag — see our detailed look at what TB-500 research has actually investigated.

Is TB 500 FDA-approved or legal in 2026?

No — and this part gets misreported constantly, so here is the careful version. TB-500 is not FDA-approved for any use. It is also not on the FDA's 503A Bulks List, the roster of substances that compounding pharmacies are permitted to use. Without that listing, there is no lawful pathway to compound or sell TB-500 as a medication in the United States today. As a thymosin beta-4 fragment, it has been treated as a 503A "Category 2" substance — flagged as posing a significant safety risk.

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed TB-500 and several other peptides under docket FDA-2025-N-6895. Ahead of that meeting, FDA staff proposed that these peptides not be added to the list, citing that they are not well physically or chemically characterized, have little human efficacy evidence, and carry unresolved safety questions — including immunogenicity risk that the agency could not rule out for injectable peptides.

Read that carefully. The committee is advisory and non-binding — a formal rule would still require notice-and-comment rulemaking. So the accurate statement is "FDA staff have proposed not to list TB-500," not "the FDA banned it." Either way, the practical reality is the same today: there is no legal, prescribed TB-500 product, and selling or using it for human therapeutic purposes violates the FD&C Act, even though buying it "for research" sits in a gray zone.

Is TB 500 banned by WADA and in sports?

Yes, clearly. Thymosin beta-4 and its derivatives, including TB-500, are on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). It is prohibited at all times — both in and out of competition — and has been since 2011. A positive test is a doping violation regardless of when the substance was used, and real sanctions have followed: athletes have received four-year bans, in some cases for combining BPC-157 and TB-500.

The takeaway for anyone in a tested sport, collegiate athletics, or a military program with drug screening is blunt: there is no "safe" competitive way to use TB-500. It is not a Specified Substance with a lighter penalty pathway — it is a straightforward S2 prohibition that puts eligibility and reputation at direct risk.

How long does TB 500 take to work, and is it safe?

No controlled human trial has ever measured how long injected TB-500 takes to work, so any timeline you read online is anecdote, not data. Because there is no approved product and no validated human dose, the more useful question is about risk — and the risk is real and present.

The clearest data comes from a 2024 peer-reviewed analysis. Researchers bought injectable peptide products from online sellers without a prescription and tested them: measured purity ran roughly 7.7% to 14.4% against the "99%" advertised, and endotoxin — a bacterial contaminant that can cause fever and worse — was present in 100% of samples, with well over half failing basic visual checks. That study examined semaglutide products, but it exposes the core problem with the entire unregulated injectable-peptide channel TB-500 is sold through.

Here is the trap most buyers fall into: a "99% pure" certificate tests identity only — whether the molecule matches the label. It does not test sterility or endotoxin. A vial can be genuinely pure on identity and still be contaminated enough to make you sick, or be the wrong sequence. There is also no chronic or high-dose human safety data for injected TB-500. One mechanism-based caution is worth naming: because thymosin beta-4 promotes angiogenesis, self-dosing is a theoretical concern for anyone with an active cancer, since new blood-vessel growth could in principle feed a tumor — a caution, not an established harm, but exactly the kind of question a controlled trial exists to answer, and none has.

We keep specific dosing figures — strictly as "what protocols have reported," never as a how-to — in our TB-500 dosage overview, where those numbers sit inside their proper safety context. No reconstitution steps or injection instructions, by design.

BPC-157 vs TB-500: what's the difference?

These two peptides are constantly discussed together, so here is the short version. BPC-157 is a 15-amino-acid peptide whose sequence traces to a protein found in gastric juice; TB-500 is the 7-amino-acid fragment of thymosin beta-4 described above. Both are studied mostly in animals, both are unapproved and not on the 503A Bulks List, and both are WADA-prohibited under S2. They are frequently combined into the "Wolverine stack," and neither has completed human trials proving injury recovery in people.

Which one is "better," whether they should be stacked, and how their proposed mechanisms differ is a topic of its own. For the full head-to-head, see our dedicated BPC-157 vs TB-500 comparison and the "Wolverine stack" explainer. If you're newer to that other peptide, start with our clear, honest guide to what BPC-157 is.

Where Nouri fits: sourcing peptides safely

Nouri's position on peptides is simple and deliberately conservative: legitimacy first. We don't sell TB-500, we don't imply it's available, and we won't put a price on a research chemical that has no legal, prescribed pathway. The reason people get hurt in this space usually isn't the molecule in theory — it's the unregulated vial in practice, the one with endotoxin in it and a certificate that only ever measured identity.

If and when a licensed, clinician-overseen, properly tested peptide option becomes available through a compliant channel, we want the people who trust us to hear about it first — from a source that led with the science and the safety, not the hype. No preselling, no promised date, no product for sale today — just first notice through a legitimate channel.

Want to be first to know if licensed peptide options become available? Join the Nouri peptide waitlist — we'll only reach out if a compliant, prescribed option opens up.

Separately, if your actual goal is metabolic health and weight management, that's a category where real, prescription-based care already exists — Nouri's medically supervised weight-loss program is one option worth understanding. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro — a different topic from peptides like TB-500, but the same principle holds: a licensed, prescribed channel beats a gray-market one every time.

Frequently asked questions

What is TB 500 and what is it used for? TB-500 is a synthetic peptide — the N-acetylated fragment Ac-LKKTETQ, corresponding to residues 17-23 of thymosin beta-4. It is marketed for tissue and injury recovery, but those uses are unproven: there is no completed published human randomized trial of injected TB-500 for any musculoskeletal or athletic indication, and it is not FDA-approved.

Is TB 500 the same as thymosin beta-4? No. Thymosin beta-4 is a full 43-amino-acid protein; TB-500 is a 7-amino-acid synthetic fragment of it. The human trial data belongs to the full protein as an eye or skin drug, not to the injected TB-500 fragment.

Is TB 500 FDA-approved or legal in 2026? No. It is not FDA-approved and not on the 503A Bulks List, so there is no legal way to compound or sell it as a medication today. In July 2026, FDA staff proposed to the advisory PCAC that it not be listed; that committee is advisory and non-binding.

Is TB 500 banned by WADA or in sports? Yes. Thymosin beta-4 and its derivatives, including TB-500, are on the WADA Prohibited List under Section S2, prohibited at all times, and have been since 2011. Athletes have received four-year bans.

Is TB 500 safe? There is no approved product and no validated human dose, so safety is not established. The bigger near-term danger is the gray market: a 2024 analysis of similar online injectables found endotoxin in 100% of samples and purity far below the advertised 99%. A "pure" label tests identity only — not sterility.

What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid peptide from a gastric protein; TB-500 is a 7-amino-acid fragment of thymosin beta-4. Both are studied mostly in animals, both are unapproved, and both are WADA-prohibited. Our dedicated comparison covers the head-to-head in full.

Sources & data

Primary sources: TB-500 fragment identity and regulatory status (Wikipedia, sourced); Xing et al., "Progress on the Function and Application of Thymosin beta-4," Frontiers in Endocrinology (2021); Bock-Marquette et al., "Thymosin beta4 activates ILK and promotes cardiac cell migration, survival and cardiac repair," Nature (2004); "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review," Applied Sciences (2026); Kleinman & Sosne, "Thymosin beta-4 Promotes Dermal Healing," Vitamins and Hormones (2016); Sosne et al., RGN-259 (Thymosin beta-4) ophthalmic Phase 3 for neurotrophic keratopathy, IJMS (2023); SEER-3 Phase 3 primary-endpoint miss (Ophthalmology Times, 2024); BSCG — TB-500 status, risks, and bans in sport; JMIR (2024) gray-market injectable quality analysis; and the Federal Register PCAC notice, docket FDA-2025-N-6895.

Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. This article is educational and is not medical advice.

Curious about legitimate, prescribed options in this space? Join the Nouri peptide waitlist — be first to know if and when a licensed, clinician-overseen peptide option becomes available.